Cellid, Co., Ltd. (299660.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩2,125 (+1.92%) as of
Key statistics
- Market cap
- 62.69B
- Dividend yield
- 0.00%
- 52-week range
- 973.00 – 4,760.00
- Profit margin
- 0.00%
- Volume
- 98.21k
About Cellid, Co., Ltd.
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seoul, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.